89781-66-8

Basic information

• Product Name: 6-(1H-imidazol-1-yl)-7,8-dihydronaphthalene-1-carboxylic acid
• Synonyms: 6-(1H-Imidazol-1-yl)-7,8-dihydronaphthalene-1-carboxylic acid;2-Naphthalenecarboxylic acid, 7,8-dihydro-6-(1H-imidazol-1-yl)-
• CAS NO: 89781-66-8
• Molecular Formula: C₁₄H₁₂N₂O₂
• Molecular Weight: 240.2573
• Mol File: 89781-66-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 485.4°C at 760 mmHg
• Flash Point: 247.4°C
• Density: 1.31g/cm³
• Vapor Pressure: 3.11E-10mmHg at 25°C
• Refractive Index: 1.669
• PKA: 4.11±0.20(Predicted)
• CAS DataBase Reference: 6-(1H-imidazol-1-yl)-7,8-dihydronaphthalene-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(1H-imidazol-1-yl)-7,8-dihydronaphthalene-1-carboxylic acid(89781-66-8)
• EPA Substance Registry System: 6-(1H-imidazol-1-yl)-7,8-dihydronaphthalene-1-carboxylic acid(89781-66-8)

Safety Data

• Hazardous Substances Data: 89781-66-8(Hazardous Substances Data)

Upstream product

• 89781-69-1 7,8-dihydro-6-(1H-imidazol-1-yl)-2-naphthalenecarbonitrile 
• 89781-70-4 1-(6-bromo-3,4-dihydronaphthalen-2-yl)-1H-imidazole 

Relevant articles and documents

N-Imidazolyl derivatives of the naphthalene and chroman rings as thromboxane A2 synthase inhibitors

A series of N-imidazol-1-yl derivatives of 1,2-dihydronaphthalene, 1,2,3,4-tetrahydronaphthalene, 2H-1-benzopyran and some related compounds were synthesized and tested as inhibitors of thromboxane A2 synthase in ex vivo experiments with orally treated rats.Some compounds showed good activity which was confirmed in experiments in vitro in rabbit whole blood.Some structural requirements for significant TxA2 synthase inhibitory activity are discussed.The selected 5,6-dihydro-7-(1H-imidazol-1-yl)-2-naphthalene-carboxylic acid (compound 7) was conformationally analysed using the Sybyl molecular model system in comparison with dazoxiben.Compound 7 was further pharmacologically investigated and on the basis of its interesting activities in vitro, ex vivo and in vivo and its low toxicity was selected for clinical investigation.

N-Imidazolyl derivatives containing naphthalene or indene nucleus

Compounds of the formula (I) STR1 wherein the symbol represents a single or a double bond; Z completes a single bond or is a --CH2 -- group; each of R1, R2, R3 and R4, which may be the same or different is (a) hydrogen; hydroxy; halogen; cyano; C1 -C6 alkyl; C1 -C6 alkoxy; a C2 -C4 acyl or C2 -C4 acylamino group; --SR', --N(R') (R"), --CH2 OR', --COR or --CH2 COR, wherein R is OR' or --N(R') (R") and each of R' and R", being the same or different, is hydrogen or C1 -C6 alkyl; or (b) one of R1, R2, R3 and R4 is 5- tetrazolyl or a group selected from --COCH2 OR', --CH=C(R')-COR and --X-C(R') (R")-COR, wherein R, R' and R" are as defined above, and X is --O--, --S--, or --NH--, and the others are as defined above under (a); one of R5 and R6 is hydrogen and the other is hydrogen, C1 -C6 alkyl, C3 -C6 cycloalkyl, or a phenyl or pyridyl ring, wherein the phenyl or pyridyl ring is unsubstituted or substituted by one to three substituents chosen from hydroxy and C1 -C4 alkoxy; or pharmaceutically acceptable salts thereof exhibit pharmaceutical activity as vasodilators or blood platelet aggregation inhibitors. Additionally, these compounds and their pharmaceutically acceptable salts are useful in the treatment of migraine, diabetic microangeopathy, rheumatoid arthritis, hypertension, peptic ulcers, osteoporosis, angina pectoris, atherosclerosis and dislipidaemies.